Corrigendum to The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis [Clin Chim Acta, 425, (2013), 163-168] Doi: 10.1016/j.cca.2013.07.030;The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 163-168

  Alharazy, Sabah Mohamed ^a   Kong, Norella C T ^a   Mohd, Marlyn ^a   Shah, Shamsul Azhar ^a   Abdul Gafor, Abdul Halim ^a   BaD́in, Arbaiyah ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Lupus nephritis; Renal disease activity; Urine neutrophil gelatinase associated lipocalin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; SERUM ALBUMIN; SPIRONOLACTONE;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBODY TITER; ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; HEMATURIA; HUMAN; LEUKOCYTURIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REMISSION; RENAL SYSTEM PARAMETERS; SENSITIVITY AND SPECIFICITY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE PROTEIN CREATININE INDEX; YOUDEN INDEX;

LUPUS NEPHRITIS; RENAL DISEASE ACTIVITY; URINE NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN;

ACUTE-PHASE PROTEINS; ADULT; BIOLOGICAL MARKERS; CREATININE; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIPOCALINS; LOGISTIC MODELS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84883325558     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.007     Document Type: Erratum

References (33)

1. Korbet S.M., Lewis E.J., Schwartz M.M., et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000, 35:904-914.
2. Seligman V.A., Lum R.F., Olson J.L., Li H., Criswell L.A. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002, 112:726-729.
3. Dooley M.A. Clinical and laboratory features of lupus nephritis. Dubois' lupus erythematosus 2007, 1112-1130. Lippincott Williams & Wilkins, Philadelphia (PA). 7th ed. D.J. Wallace, B.H. Hahn (Eds.).
4. Reyes-Thomas J., Blanco I., Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011, 40(3):138-150.
5. Dooley M.A., Hogan S., Jennette C., Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997, 51(4):1188-1195.
6. Samanta A., Feehally J., Roy S., Nichol F.E., Sheldon P.J., Walls J. High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis 1991, 50:490-492.
7. Bono L., Cameron J.S., Hicks J.A. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999, 4:211-218.
8. Mok C.C. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006, 36(2):71-81.
9. Schwartz M.M., Kawala K.S., Corwin H.L., Lewis E.J. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987, 32(2):274-279.
10. Steinberg A.D., Steinberg S.C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991, 34(8):945-950.
11. Kong N.C.T. Editorial: systemic lupus erythematosus in Southeast Asia. J Am Med Assoc Southeast Asia 1993, 8-10.
12. Kong N.C.T. SLE activity measures and prognosis. Malays J Derm 1996, 9:15-24.
13. Schwartz N., Michaelson J.S., Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 2007, 1109:265-274.
14. Cowland J.B., Sorensen O.E., Sehested M., Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1, but not by TNF. J Immunol 2003, 171:6630-6639.
15. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
16. Zappitelli M., Washburn K.K., Arikan A.A., et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007, 11:R84.
17. Hirsch R., Dent C., Pfriem H., et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007, 22:2089-2095.
18. Ling W., Zhaohui N., Ben H., et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 2008, 108(3):176-181.
19. Alharazy S.M., Kong N., Saidin R., et al. Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after coronary angiography. Angiology 2013, 10.1177/0003319712474947.
20. Pawar R.D., Pitashny M., Gindea S., et al. Neutrophil gelatinase associated lipocalin is instrumental in the pathogenesis of antibody-mediated nephritis. Arthritis Rheum 2012, 64:1620-1631.
21. Brunner H.I., Mueller M., Rutherford C., et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006, 4:2577-2584.
22. Pitashny M., Schwartz N., Qing X., et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007, 56:1894-1903.
23. Rubinstein T., Pitashny M., Levine B., et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010, 49(5):960-971.
24. Suzuki M., Wiers K.M., Klein-Gitelman M.S., et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008, 23(3):403-412.
25. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
26. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI: a disease activity index: for lupus patients. Arthritis Rheum 1992, 35(6):630-640.
27. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
28. Alharazy S.M., Kong N.C.T., Mohd M., et al. The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis. Clin Chim Acta 2013, [in press]. 10.1016/j.cca.2013.07.030.
29. Loo C.Y., Kong N.C.T., Shahrir M.S., et al. Renal biopsies in lupus nephritis, 1987-2007. J Am Soc Nephrol 2008, [PUB 678:966A].
30. Hinze C.H., Suzuki M., Klein-Gitelman M., et al. Neutrophil gelatinase associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009, 60:2772-2781.
31. Bolignano D., Donato V., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008, 52(3):595-605.
32. Eriksson C., Kokkonen H., Johansson M., Hallmans G., Wadell G., Rantapaa-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011, 13:R30.
33. Moroni G., Radice A., Giammarresi G., et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009, 68:234-237.